Skip to main content
SpringerLink
Log in

Pulmonary Hypertension in Interstitial Lung Disease

  • Chapter
  • First Online:
Diffuse Lung Disease

  • 1519 Accesses

Abstract

Pulmonary hypertension (PH) may complicate the course of many forms of interstitial lung disease (ILD) and has been shown to portend a worse outcome. The etiology of PH is likely multifactorial and might differ among the diseases with variable contributions of many potential factors. Whether the impact of PH and thereby the course of the disease can be modified by therapy requires further study. This chapter provides an overview of the prevalence, epidemiology, pathophysiology, diagnosis, and clinical implications of PH in ILD. The potential role of therapy is discussed and a review of current treatment trials is provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Thoracic Society, European Respiratory Society. Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. General principles and recommendations. Am J Respir Crit Care Med. 2002;165:277–304.

    Google Scholar 

  2. Thannickal VJ, Toews GB, White ES, Lynch III JP, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395–417.

    Article  PubMed  CAS  Google Scholar 

  3. Strange C, Highland K. Pulmonary hypertension in ILD. Curr Opin Pulm Med. 2005;11:452–5.

    Article  PubMed  Google Scholar 

  4. Simmoneau G, Robins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43–S54.

    Article  Google Scholar 

  5. Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Curr Opin Pulm Med. 2003;9:426–30.

    Article  PubMed  Google Scholar 

  6. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573–619.

    Article  PubMed  Google Scholar 

  7. Chronic Cor Pulmonale. Report of an expert committee. Circulation. 1963;27(4):594–615.

    Google Scholar 

  8. Fartoukh M, Humbert M, Capron F, et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med. 2000;161:216–23.

    PubMed  CAS  Google Scholar 

  9. Dauriat G. Lung transplantation for pulmonary Langerhans’ cell histiocytosis: a multicenter analysis. Transplantation. 2006;81(5):746–50.

    Article  PubMed  Google Scholar 

  10. Chaowalit N, Pellikka PA, Decker PA, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc. 2004;79(10):1269–75.

    Article  PubMed  Google Scholar 

  11. Harari S, Brenot F, Barberis M, Simmoneau G. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest. 1997;111(4):1142–4.

    Article  PubMed  CAS  Google Scholar 

  12. Lettieri C, Nathan SD, Barnett S, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746–52.

    Article  PubMed  Google Scholar 

  13. Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128:2393–9.

    Article  PubMed  Google Scholar 

  14. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30(4):715–21.

    Article  PubMed  CAS  Google Scholar 

  15. Nathan SD, Ahmad S, Shlobin OA, Barnett SD. Correlation of PFT with PAH in patients with IPF [abstract]. Proc Am Thorac Soc. 2006;3:A103.

    Article  Google Scholar 

  16. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088–93.

    Article  PubMed  CAS  Google Scholar 

  17. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003;30:2398–405.

    PubMed  Google Scholar 

  18. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151–7.

    Article  PubMed  Google Scholar 

  19. Trad S, Amoura Z, Beigelman C, et al. PAH is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. 2006;54:184–91.

    Article  PubMed  Google Scholar 

  20. Steen V, Medsger Jr TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516–22.

    Article  PubMed  Google Scholar 

  21. Handa T, Nagai S, Miki S, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006;129:1246–52.

    Article  PubMed  Google Scholar 

  22. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25:783–8.

    Article  PubMed  CAS  Google Scholar 

  23. Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest. 2003;124:922–8.

    Article  PubMed  Google Scholar 

  24. Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest. 2005;128:1483–9.

    Article  PubMed  Google Scholar 

  25. Taveira-DaSilva AM, Hathaway OM, Sachdev V, Shizukuda Y, Birdsall CW, Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest. 2007;132(5):1573–8.

    Article  PubMed  Google Scholar 

  26. Portier F, Lerebours-Pigeonniere G, Thiberville L, et al. Sarcoidosis simulating pulmonary veno-occlusive disease. Rev Mal Respir. 1991;8(1):101–2.

    PubMed  CAS  Google Scholar 

  27. Morgan JM, Griffiths M, du Bois RM, Evans TW. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest. 1991;99:551–6.

    Article  PubMed  CAS  Google Scholar 

  28. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006;61:68–74.

    Article  PubMed  CAS  Google Scholar 

  29. Colombat M, Mal H, Groussard O, et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol. 2007;38(1):60–5.

    Article  PubMed  CAS  Google Scholar 

  30. Palmer SM, Robinson LJ, Wang A, Gossage JR, Bashore T, Tapson VF. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest. 1998;113:237–40.

    Article  PubMed  CAS  Google Scholar 

  31. Farber HW, Graven KK, Kokolski G, Korn JH. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol. 1999;26:1195–6.

    PubMed  CAS  Google Scholar 

  32. Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis. 2002;45:225–34.

    Article  PubMed  Google Scholar 

  33. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol. 2006;47(4):799–803.

    Article  PubMed  Google Scholar 

  34. Yamakami T, Taguchi O, Gabazza EC, et al. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease: relation with pulmonary HTN during exercise. Eur Respir J. 1997;10:2055–60.

    Article  PubMed  CAS  Google Scholar 

  35. MacLean MR. Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension? J Lab Clin Med. 1999;134:105–14.

    Article  PubMed  CAS  Google Scholar 

  36. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 2007;131:657–63.

    Article  PubMed  Google Scholar 

  37. Galie N, Manes A, Farahani KV, et al. PAH associated with CTDs. Lupus. 2005;14:713–7.

    Article  PubMed  CAS  Google Scholar 

  38. Fahy GJ, Marwick T, McCreery CJ, Quigley PJ, Maurer BJ. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest. 1996;109:62–6.

    Article  PubMed  CAS  Google Scholar 

  39. Magro CM, Allen J, Pope-Harman A, et al. The role of microvascular injury in the evolution of idiopathic pulmonary fibrosis. Am J Clin Pathol. 2003;119:556–67.

    Article  PubMed  Google Scholar 

  40. Panos R. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990;88(4):396–404.

    Article  PubMed  CAS  Google Scholar 

  41. Nathan SD, Barnett SD, Urban BA, Nowalk C, Moran BR, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest. 2003;123:1758–63.

    Article  PubMed  Google Scholar 

  42. Mejía M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009;136(1):10–5.

    Article  PubMed  Google Scholar 

  43. Perez-Padilla R, West P, Lertzman M, Kryger MH. Breathing during sleep in patients with interstitial lung disease. Am Rev Respir Dis. 1985;132:224–9.

    PubMed  CAS  Google Scholar 

  44. Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med. 2009;103:180–6.

    Article  PubMed  Google Scholar 

  45. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003;62:97–9.

    Article  PubMed  CAS  Google Scholar 

  46. Zisman DA, Karlamangla AS, Ross DJ, et al. High resolution CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2007;132:773–9.

    Article  PubMed  Google Scholar 

  47. Yock P. Noninvasive estimation of the right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 1984;70(4):657–62.

    Article  PubMed  CAS  Google Scholar 

  48. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615–21.

    Article  PubMed  Google Scholar 

  49. Arcasoy S, Chrstie J, Ferrari V, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167:735–40.

    Article  PubMed  Google Scholar 

  50. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:40S–7.

    Article  PubMed  Google Scholar 

  51. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917–28.

    Article  PubMed  Google Scholar 

  52. Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54:S85–96.

    Article  PubMed  Google Scholar 

  53. Minai OA, Santucruz JF, Thuita L, et al. Severe pulmonary hypertension in IPF: characteristics and implications (ISHLT 2009 abstract). J Heart Lung Transplant. 2009;28(2S):S109.

    Article  Google Scholar 

  54. Bye PTP, Issa F, Berthon-Jones M, Sullivan CE. Studies of oxygenation during sleep in patients with interstitial lung disease. Am Rev Respir Dis. 1984;129:27–32.

    PubMed  CAS  Google Scholar 

  55. Papadopoulis CE, Pitsiou G, Karamitsos TD, et al. Left ventricular diastolic dysfunction in IPF: a tissue Doppler ECG study. Eur Respir J. 2008;31:701–6.

    Article  Google Scholar 

  56. Corte TJ, Talbot S, Wort SJ, et al. Nocturnal desaturation is associated with pulmonary hypertension in patients with mild to moderate interstitial lung disease. Am J Respir Crit Care Med. 2009;179:A4057 (abstract).

    Google Scholar 

  57. Shitrit D, Rusanov V, Peled N, Amital A, Fuks L, Kramer MR. The 15-step oximetry test: a reliable tool to identify candidates for lung transplantation among patients with idiopathic pulmonary fibrosis. J Heart Lung Transplant. 2009;28:328–33.

    Article  PubMed  Google Scholar 

  58. Benyuones B, Crestani B, Couvelard A, Vissuzaine C, Aubter M. Steroid-responsive pulmonary hypertension in a patient with Langerhans’ cell granulomatosis (histiocytosis X). Chest. 1996;110:284–6.

    Article  Google Scholar 

  59. Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest. 1990;97:500–2.

    Article  PubMed  CAS  Google Scholar 

  60. Gluskowski J, Hawrylkiewicz I, Zych D, Zielinski J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J. 1990;3:403–7.

    PubMed  CAS  Google Scholar 

  61. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475–82.

    Article  PubMed  CAS  Google Scholar 

  62. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1):78–84. Suppl S.

    Article  Google Scholar 

  63. Krowka MJ, Ahmad S, Andrade JA, et al. A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary fibrosis. Chest. 2007;132:633S (abstract).

    Google Scholar 

  64. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med. 1999;160:600–7.

    PubMed  CAS  Google Scholar 

  65. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360(9337):895–900.

    Article  PubMed  CAS  Google Scholar 

  66. Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007;131:897–9.

    Article  PubMed  Google Scholar 

  67. The Idiopathic Pulmonary Fibrosis Clinical Research Network. A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis. N Engl J Med. 2010; 363:620–628.

    Google Scholar 

  68. King Jr. TE, Brown KK, Raghu G, et al. BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. Amer Jour Respir Crit Care Med. 2011;184:92–99.

    Article  PubMed  CAS  Google Scholar 

  69. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:A3357 (abstract).

    Google Scholar 

  70. http://clinicaltrials.gov/ct2/show/NCT00879229

  71. Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest. 2001;120:866–72.

    Article  PubMed  CAS  Google Scholar 

  72. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated ­pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest. 2006;130(5):1481–8.

    Article  PubMed  CAS  Google Scholar 

  73. Minai O, Sahoo D, Chapman J, Mehta AC. Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. Respir Med. 2008;102(7):1015–20.

    Article  PubMed  Google Scholar 

  74. Barnett CF, Bonura EJ, Nathan SD, et al. Treatment of sarcoidosis-associated pulmonary hypertension. A Two-center experience. Chest. 2009;135(6):1455–61.

    Article  PubMed  Google Scholar 

  75. Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil? J Heart Lung Transplant. 2008;27(3):329–34.

    Article  PubMed  Google Scholar 

  76. Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J. 2005;32(3):405–10.

    PubMed  Google Scholar 

  77. Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:108–16.

    PubMed  Google Scholar 

  78. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008;31:1357–67.

    Article  PubMed  CAS  Google Scholar 

  79. Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension in patients with bronchiolitis obliterans syndrome listed for retransplantation. Am J Transplant. 2008;8(7):1506–11.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA

    Oksana A. Shlobin MD, FCCP & Steven D. Nathan MD, FCCP

Authors
  1. Oksana A. Shlobin MD, FCCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven D. Nathan MD, FCCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oksana A. Shlobin MD, FCCP .

Editor information

Editors and Affiliations

  1. University of Cincinnati, College of Medicine, Department of Internal Medicine, Eden Ave, Cincinnati, 45267-0565, Ohio, USA

    Robert P. Baughman

  2. of Respiratory Medicine, Imperial College, Emeritus Professor, Grand Ave 14, London, N10 3BB, United Kingdom

    Roland M. du Bois

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Shlobin, O.A., Nathan, S.D. (2012). Pulmonary Hypertension in Interstitial Lung Disease. In: Baughman, R., du Bois, R. (eds) Diffuse Lung Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9771-5_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9771-5_8

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-9770-8

  • Online ISBN: 978-1-4419-9771-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation